Acellular dermal matrix (ADM) is a biologically derived product, which is devoid of cells. Acellular dermal matrices were initially used in the resurfacing of burn injuries, abdominal wall repair, tympanic membrane replacement, dural repairs, and gingival grafting. Now ADMs are mostly used in breast surgery and plastic surgery. Also, acellular dermal matrices has a wide application in the management of acute wounds such as burns, traumatic wounds, cancer, and infections, they are also used in the management of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcer, and others and they are also used in the most of the reconstruction procedures such as abdominal wall procedures, which include hernia repair, breast procedures include breast augmentation, orthopedic procedures, and others.
The global acellular dermal matrices market is estimated to be valued at US$ 7,014.0 million in 2021 and is expected to exhibit a CAGR of 12.1% over the forecast period (2021-2028).
Figure 1. Global Acellular Dermal Matrices Market Value (US$ Mn), and Y-o-Y Growth (%), 2018-2028
Increasing number of product launches by key playe rs are expected to drive the market growth over the forecast period.
The key players operating in the global acellular dermal matrices market are focusing on launches and approvals of technologically advanced acellular dermal matrices in the market, which is expected to drive the market growth over the forecast period. For instance, in April 2021, MedSkin Solutions Dr. Suwelack AG, a Germany-based specialized biotech company, launched two new MatriDerm products, MatriDerm Flex Dermal Matrix and MatriDerm Fenestrated Dermal Matrix. The two new products are introduced as an extension of MatriDerm’s product portfolio that offers more flexibility to surgeons for the treatment of complex wounds when it comes to one- and two-stage surgical procedures, which utilizes a split-thickness skin graft.
Acellular Dermal Matrices Market Report Coverage
||Market Size in 2021:
||US$ 7,014.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 15,648.1 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Origin: Human Dermis, Porcine Dermis, Bovine Dermis
- By Application: Acute Wounds:(Burns, Trauma, Cancers, Infections), Chronic Wounds:(Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Ulcer, and Others), Reconstruction Procedures:(Abdominal Wall Procedures, Breast Procedures, Orthopedic Procedures, and Others)
- By Place of Setting: Hospitals(In- patient and Out- patient), Ambulatory Surgical Centers, Office Based
Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
- The rising number of surgeries
- Increasing product launches and approvals
|Restraints & Challenges:
- Complications of acellular dermal matrices in breast surgeries and plastic surgeries
- Product recalls
Figure 2. Global Acellular Dermal Matrices Market Share (%), by Application, 2021
Global Acellular Dermal Matrices market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe. The coronavirus (COVID 19) pandemic and lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Therefore, the governments and government agencies globally are taking various initiatives to combat the spread of COVID-19.
For instance, the Australian Society of Plastic Surgeons (ASPS), the Australian government organization, and BreastSurgANZ announced various guidelines and regulations for reconstruction procedures. These guidelines included surgeons to take informed consent from patients for performing reconstructive surgery during COVID-19 pandemic, inform about the potential consequences of the surgery done during COVID-19 to the patient and others, to delay the reconstruction procedures if not urgent, to delay immediate autologous flap reconstruction for breast reconstruction. While the regulations stated that the reconstructive surgeons should address only the cancer-related surgeries during COVID-19.
Global Acellular Dermal Matrices market: Restraint
Complications and side effects associated with acellular dermal matrices in breast and plastic surgery is expected to restraint growth of the global acellular dermal matrices market over the forecast period. According to the article published in Plastic and Reconstructive Surgery Journal in February 2019, in the U.S., the rate of plastic surgeries are high as compared to other countries. Moreover, the rate of side-effects and complications associated with plastic surgery such as skin necrosis are caused in 8-15% of the patients undergoing plastic surgery.
Major players operating in the global acellular dermal matrices market include Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.